BioSpace News Archive

The National Comprehensive Cancer Network® —a not-for-profit alliance of leading academic cancer centers—announced Crystal S. Denlinger, MD, FACP, as incoming Chief Executive Officer.

AiCuris announced today that it has received milestone payments in the amount of EUR €30 million from its licensing partner MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA, (MRK)) following U.S. Food and Drug Administration (FDA) approval for first-in-class antiviral agent PREVYMIS ® in a new indication.

Mallinckrodt plc announced it has entered into a Restructuring Support Agreement with a substantial majority of each of the Company’s first and second lien debtholders and the Opioid Master Disbursement Trust II on the terms of a comprehensive financial restructuring plan that will reduce the Company’s total funded debt by approximately $1.9 billion, increase free cash flow generation, extend maturity runway and better position the business for long-term success.

Adial Pharmaceuticals, Inc. announced that it received notice from Nasdaq on August 21, 2023 that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550.

ABVC BioPharma, Inc today announced that 60 subjects had been enrolled and 53 had completed the eight-week study for the Company’s ADHD Phase IIb clinical study.

BioSig Technologies, Inc., a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, announced a subscription model for its PURE EP™ Platform.

Altamira Therapeutics Ltd. today announced that its founder, Chairman, and CEO Thomas Meyer will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference, being held virtually and in person on September 11-13, 2023, at Lotte New York Palace Hotel in New York City.

Curi Bio proudly announces two recent SBIR grants worth $4.4 million from the National Institutes of Health to support its pioneering work on implementing human models to advance discovery of the next generation of medicines.

Exicure, Inc., historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, announced that, effective as of August 21, 2023, Paul Kang, a Class III director, was appointed as Chief Executive Officer of the Company and Jiyoung Hwang, a Class I director, was appointed as Chief Financial Officer of the Company.

Welldoc®, a digital health leader revolutionizing chronic care, today announced the receipt of its 11th 510(k) clearance from the Food and Drug Administration (FDA) for its award-winning diabetes digital health solution, BlueStar®.